Cargando…

Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)

BACKGROUND: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) patients with stereotactic radiation. We aimed to address whether patients definitively treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikitas, John, Roach, Michael, Robinson, Cliff, Bradley, Jeffrey, Huang, Jiayi, Perkins, Stephanie, Tsien, Christina, Abraham, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956672/
https://www.ncbi.nlm.nih.gov/pubmed/31956701
http://dx.doi.org/10.1016/j.ctro.2019.12.001
_version_ 1783487187005734912
author Nikitas, John
Roach, Michael
Robinson, Cliff
Bradley, Jeffrey
Huang, Jiayi
Perkins, Stephanie
Tsien, Christina
Abraham, Christopher
author_facet Nikitas, John
Roach, Michael
Robinson, Cliff
Bradley, Jeffrey
Huang, Jiayi
Perkins, Stephanie
Tsien, Christina
Abraham, Christopher
author_sort Nikitas, John
collection PubMed
description BACKGROUND: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) patients with stereotactic radiation. We aimed to address whether patients definitively treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS) had favorable outcomes with local therapy. MATERIALS AND METHODS: We reviewed a database of patients receiving lung SBRT as well as a database for brain metastasis patients treated with SRS between June 2004 and January 2016. We selected for cT1-2aN0M1 NSCLC patients with brain metastases and calculated their overall survival (OS), freedom from progression (FFP), and local control (LC) rates. RESULTS: Six patients had oligometastatic NSCLC with 1–3 synchronous brain metastases treated with lung SBRT and brain SRS. No patients received immunotherapy and two-thirds did not receive systemic therapy. Median follow-up was 9 months for the entire cohort (range, 2–95 months) and 95 months for the surviving patient. Median OS was 12.4 months (95% confidence interval [CI], 7–18 months). At 1 year, patients had 67% OS (95% CI, 29–100%), 17% FFP (95% CI, 0–46%), and 100% LC. Their brain disease had 80% 1-year LC (95% CI, 45–100%) and 53% 1-year FFP (95% CI, 5–100%). Two patients had no distant progression, two had brain progression, one had adrenal gland progression, and one had bone and liver progression. CONCLUSION: In patients presenting with oligometastatic lung cancer limited to the brain, treatment with both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS.
format Online
Article
Text
id pubmed-6956672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69566722020-01-17 Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) Nikitas, John Roach, Michael Robinson, Cliff Bradley, Jeffrey Huang, Jiayi Perkins, Stephanie Tsien, Christina Abraham, Christopher Clin Transl Radiat Oncol Article BACKGROUND: There is increasing interest in treating oligometastatic non-small cell lung cancer (NSCLC) patients with stereotactic radiation. We aimed to address whether patients definitively treated with synchronous thoracic stereotactic body radiation therapy (SBRT) and brain stereotactic radiosurgery (SRS) had favorable outcomes with local therapy. MATERIALS AND METHODS: We reviewed a database of patients receiving lung SBRT as well as a database for brain metastasis patients treated with SRS between June 2004 and January 2016. We selected for cT1-2aN0M1 NSCLC patients with brain metastases and calculated their overall survival (OS), freedom from progression (FFP), and local control (LC) rates. RESULTS: Six patients had oligometastatic NSCLC with 1–3 synchronous brain metastases treated with lung SBRT and brain SRS. No patients received immunotherapy and two-thirds did not receive systemic therapy. Median follow-up was 9 months for the entire cohort (range, 2–95 months) and 95 months for the surviving patient. Median OS was 12.4 months (95% confidence interval [CI], 7–18 months). At 1 year, patients had 67% OS (95% CI, 29–100%), 17% FFP (95% CI, 0–46%), and 100% LC. Their brain disease had 80% 1-year LC (95% CI, 45–100%) and 53% 1-year FFP (95% CI, 5–100%). Two patients had no distant progression, two had brain progression, one had adrenal gland progression, and one had bone and liver progression. CONCLUSION: In patients presenting with oligometastatic lung cancer limited to the brain, treatment with both lung SBRT and brain SRS achieves good LC of all sites with encouraging OS. Elsevier 2019-12-11 /pmc/articles/PMC6956672/ /pubmed/31956701 http://dx.doi.org/10.1016/j.ctro.2019.12.001 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Nikitas, John
Roach, Michael
Robinson, Cliff
Bradley, Jeffrey
Huang, Jiayi
Perkins, Stephanie
Tsien, Christina
Abraham, Christopher
Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title_full Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title_fullStr Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title_full_unstemmed Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title_short Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
title_sort treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (srs) and stereotactic body radiation therapy (sbrt)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956672/
https://www.ncbi.nlm.nih.gov/pubmed/31956701
http://dx.doi.org/10.1016/j.ctro.2019.12.001
work_keys_str_mv AT nikitasjohn treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT roachmichael treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT robinsoncliff treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT bradleyjeffrey treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT huangjiayi treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT perkinsstephanie treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT tsienchristina treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt
AT abrahamchristopher treatmentofoligometastaticlungcancerwithbrainmetastasesusingstereotacticradiosurgerysrsandstereotacticbodyradiationtherapysbrt